



JFW
Dkt. #639-B-PCT-US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Nai-Kong CHEUNG

U.S. Serial No.: 10/621,027, continuation-in-part of International Application No. PCT/US02/01276, filed January 15, 2002, claiming benefit of U.S. Serial No. 60/261,911, filed January 16, 2001

Filed Date : July 16, 2003

For : THERAPY-ENHANCING GLUCAN

Law Offices of Albert Wai-Kit Chan, LLC
World Plaza, Suite 604
141-07 20th Avenue
Whitestone, NY 11357

November 22, 2004

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir/Madam:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Applicant hereby submits this Supplemental Information Disclosure Statement in accordance with their duty of disclosure under 37 C.F.R. §1.56. Applicant originally filed an Information Disclosure Statement for the above-identified application on July 16, 2003 and Supplemental Information Disclosure Statements on April 12, 2004, September 24, 2004 and November 8, 2004. Applicant would like to direct the Examiner's attention to the following references which are listed below as **Exhibits 1-6** and on Forms PTO/SB/08A and PTO/SB/08B (**Exhibit A**, 2 pages). Further, Applicant's attorney's office may be contacted in the event that the Examiner would like a copy of all references filed with the July 16, 2003 Information Disclosure Statement, April 12, 2004 Supplemental Information Disclosure Statement, September 24, 2004, and November 8, 2004 Supplemental Information Disclosure Statements. The following references are attached:

Applicant : Nai-Kong CHEUNG
U.S. Serial No.: 10/621,027
Filed : July 16, 2003
Page : 2

1. U.S. Patent No. 5,130,127, filed May 28, 1991, issued July 14, 1992 [Exhibit 1]
2. International Publication No. WO 01/62283 A2, Published Application of International Application No. PCT/IB01/00144, February 2, 2001 [Exhibit 2]
3. Ross, et al. Therapeutic intervention with complement and beta-glucan in cancer, Immunopharmacology 42(1999), 61-74 [Exhibit 3]
4. Vetvicka, et al. Pilot Study: Orally-administered Yeast beta-(1,3)-glucan prophylactically protects against anthrax infection and cancer in mice. Journ Ameri Nutraceutical Assoc, Vol. 5:2, April 22, 2002 [Exhibit 4]
5. Cheung, N.K. Orally administered beta-glucans enhance anti-tumor effects of monoclonal antibodies. Cancer Immunother. 2002 Nov; 51(10):557-64 [Exhibit 5]
6. Suzuki, et al. Effect of orally administered β -glucan on macrophage function in mice. Int. J. Immunopharmacology 12:6, 675-684, 1990 [Exhibit 6]

If a telephone interview would be of assistance in advancing prosecution of the subject application, Applicant's undersigned attorney invites the Examiner to telephone him at the number provided below.

Applicant : Nai-Kong CHEUNG
U.S. Serial No.: 10/621,027
Filed : July 16, 2003
Page : 3

No fee is deemed necessary in connection with the filing of this Supplemental Information Disclosure Statement. However, if any fee is required, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 50-1891.

I hereby certify that this paper is being deposited this date with the U.S. Postal Service with sufficient postage for first class mail addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Albert Wai-Kit Chan 11/22/04
Albert Wai-Kit Chan Date
Reg. No. 36,479

Respectfully submitted,

Albert Wai-Kit Chan

Albert Wai-Kit Chan
Registration No. 36,479
Attorney for Applicant
Law Offices of
Albert Wai-Kit Chan, LLC
World Plaza, Suite 604
141-07 20th Avenue
Whitestone, New York 11357
Tel: (718) 357-8836
Fax: (718) 357-8615
E-mail: kitchanlaw@aol.com



PTO/SB/08A (04-03)

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

(Use as many sheets as necessary)

Sheet 1 of 2

Complete if Known

Application Number	10/621,027
Filing Date	July 16, 2003
First Named Inventor	Nai-Kong Chueng
Art Unit	
Examiner Name	

Attorney Docket Number 639-B-PCT-US

U. S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.¹ Applicant's unique citation designation number (optional).² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04.³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments and/or amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (04-03)

Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Complete if Known**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet	2	of	2	Attorney Docket Number	639-B-PCT-US
-------	---	----	---	------------------------	--------------

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	3	Ross, et al. Therapeutic intervention with complement and beta-glucan in cancer, Immunopharmacology 42(1999), 61-74	
	4	Vetvicka, et al. Pilot Study: Orally-administered Yeast beta-(1,3)-glucan prophylactically protect against anthrax infection and cancer in mice. Journ Amer Nutraceutical Assoc, Vol. 5:2, April 22, 2002	
	5	Cheung, N.K. Orally administered beta-glucans enhance anti-tumor effects of monoclonal antibodies. Cancer Immunother. 2002 Nov; 51(10):557-64	
	6	Suzuki, et al. Effect of orally administered beta-glucan on macrophage function in mice. Int. J. Immunopharmacology 12:6, 675-684, 1990	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.